A month has gone by since the last earnings report for BioMarin Pharmaceutical (BMRN). Shares have added about 0.2% in that time frame, underperforming the S&P 500. Will the recent positive trend ...

Shares of BioMarin Pharmaceutical BMRN were up 3% in pre-market trading today after the company reported positive top-line ...

Tested in a condition known as ENPP1 deficiency, the treatment failed a trial goal that’s important to regulators, spurring doubts about its approval prospects.

Shares of biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) jumped 7.3% in the afternoon session after the company ...

BioMarin Pharmaceutical, a San Rafael biotech company known for treating extremely rare diseases, said Wednesday it’s laying off 225 workers, most of whom live and work in California. The cuts come ...

The success came two days after a Phase 3 setback for another experimental drug and helps improve the position of Voxzogo ...

After quite the regulatory process, with Roctavian (valoctocogene roxaparvovec) BioMarin has a potential blockbuster. On June 29th, Roctavian became the first gene therapy approved in the U.S. in the ...

BioMarin, the pharmaceutical company based in San Rafael, is laying off 170 employees, or about 5% of its workforce of 3,400. The move followed a “strategic assessment of research and development ...

With phase 3 results that have “exceeded” BioMarin’s expectations, according to R&D chief Greg Friberg, M.D., the California ...

Jean-Jacques Bienaimé, who over the course of nearly two decades grew BioMarin Pharmaceutical’s portfolio from a single commercialized asset to multiple marketed products—including a landmark approval ...

BioMarin disclosed late Wednesday that longtime CEO JeanJacques (JJ) Bienaimé is retiring effective December 1 and will be succeeded by Alexander Hardy, who is currently the CEO of Genentech at Roche.

A one-time BioMarin Pharmaceutical treatment that fixes the problem at the root of hemophilia A has finally won FDA approval, making it the first gene therapy authorized for the inherited bleeding ...